BACKGROUND: A high survival rate can be achieved in patients with severe acute respiratory distress syndrome (ARDS) using extracorporeal membrane oxygenation (ECMO). The technique and the costs are, however, debated and follow-up studies in survivors are few. The aim of this study was to evaluate long-term pulmonary health after ECMO and severe ARDS. METHODS: Twenty-one long-term survivors of severe ARDS and ECMO were studied in a follow-up program including high-resolution computed tomography (HRCT) of the lungs, extensive pulmonary function tests, pulmonary scintigraphy and the pulmonary disease-specific St George's Respiratory Questionnaire (SGRQ). RESULTS: The majority of patients had residual lung parenchymal changes on HRCT suggestive of fibrosis, but the extension of morphologic abnormalities was limited and without the typical anterior localization presumed to indicate ventilator-associated lung injury. Pulmonary function tests revealed good restitution with mean values in the lower normal range, while T(1/2) for outwash of inhaled isotope was abnormal in all patients consistent with subclinical obstructivity. Most patients had reduced health-related quality of life (HRQoL), according to the SGRQ, but were stating less respiratory symptoms than conventionally treated ARDS patients in previous studies. The majority were integrated in normal work. CONCLUSION: The majority of ECMO-treated ARDS patients have good physical and social functioning. However, lung parenchymal changes on HRCT suggestive of fibrosis and minor pulmonary function abnormalities remain common and can be detected more than 1 year after ECMO. Furthermore, most patients experience a reduction in HRQoL due to the pulmonary sequelae.
BACKGROUND: A high survival rate can be achieved in patients with severe acute respiratory distress syndrome (ARDS) using extracorporeal membrane oxygenation (ECMO). The technique and the costs are, however, debated and follow-up studies in survivors are few. The aim of this study was to evaluate long-term pulmonary health after ECMO and severe ARDS. METHODS: Twenty-one long-term survivors of severe ARDS and ECMO were studied in a follow-up program including high-resolution computed tomography (HRCT) of the lungs, extensive pulmonary function tests, pulmonary scintigraphy and the pulmonary disease-specific St George's Respiratory Questionnaire (SGRQ). RESULTS: The majority of patients had residual lung parenchymal changes on HRCT suggestive of fibrosis, but the extension of morphologic abnormalities was limited and without the typical anterior localization presumed to indicate ventilator-associated lung injury. Pulmonary function tests revealed good restitution with mean values in the lower normal range, while T(1/2) for outwash of inhaled isotope was abnormal in all patients consistent with subclinical obstructivity. Most patients had reduced health-related quality of life (HRQoL), according to the SGRQ, but were stating less respiratory symptoms than conventionally treated ARDSpatients in previous studies. The majority were integrated in normal work. CONCLUSION: The majority of ECMO-treated ARDSpatients have good physical and social functioning. However, lung parenchymal changes on HRCT suggestive of fibrosis and minor pulmonary function abnormalities remain common and can be detected more than 1 year after ECMO. Furthermore, most patients experience a reduction in HRQoL due to the pulmonary sequelae.
Authors: D Chiumello; P Taccone; V Berto; A Marino; G Migliara; M Lazzerini; L Gattinoni Journal: Intensive Care Med Date: 2011-12-21 Impact factor: 17.440
Authors: Paolo Meani; Matteo Matteucci; Federica Jiritano; Dario Fina; Francesco Panzeri; Giuseppe M Raffa; Mariusz Kowalewski; Nuccia Morici; Giovanna Viola; Alice Sacco; Fabrizio Oliva; Amal Alyousif; Sam Heuts; Martijn Gilbers; Rick Schreurs; Jos Maessen; Roberto Lorusso Journal: Ann Cardiothorac Surg Date: 2019-01
Authors: Margaret S Herridge; Marc Moss; Catherine L Hough; Ramona O Hopkins; Todd W Rice; O Joseph Bienvenu; Elie Azoulay Journal: Intensive Care Med Date: 2016-03-30 Impact factor: 17.440
Authors: Antonio T Hernandez Conte; David Ng; Danny Ramzy; Deanna Dilibero; Troy M LaBounty; Cyril Gaultier; Elizabeth C Behringer Journal: Tex Heart Inst J Date: 2018-08-01
Authors: E R Kurniawati; V G H Rutjens; N P A Vranken; T S R Delnoij; R Lorusso; I C C van der Horst; J G Maessen; P W Weerwind Journal: Qual Life Res Date: 2021-04-07 Impact factor: 4.147
Authors: Amelia C Trombetta; Guilherme B Farias; André M C Gomes; Ana Godinho-Santos; Pedro Rosmaninho; Carolina M Conceição; Joel Laia; Diana F Santos; Afonso R M Almeida; Catarina Mota; Andreia Gomes; Marta Serrano; Marc Veldhoen; Ana E Sousa; Susana M Fernandes Journal: Front Immunol Date: 2021-06-23 Impact factor: 7.561
Authors: Carol L Hodgson; Kate Hayes; Tori Everard; Alistair Nichol; Andrew R Davies; Michael J Bailey; David V Tuxen; David J Cooper; Vin Pellegrino Journal: Crit Care Date: 2012-10-19 Impact factor: 9.097